Member Info for schlemiel

LONDON and PHILADELPHIA - January 16, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced compelling new data in patients with salivary gland cancer (SGC) from the ongoing Phase 1a trial of AVA6000 in patients with FAP-positive solid tumors. The data demonstrates robust and meaningful tumor shrinkage in patients with salivary gland cancers, a disease with no standard therapy defined in the metastatic setting.

AVA6000 is the first peptide drug conjugate in Avacta's pipeline and consists of doxorubicin conjugated with Avacta's proprietary pre|CISION® peptide, that is specifically cleaved by fibroblast activation protein-alpha (FAP) in the tumor microenvironment.

The key findings include:

· Among 10 patients treated at the dose of 250 mg/m2 and above, five patients demonstrate tumor shrinkage (one partial and four minor responses)

· Six of these 10 patients are continuing treatment and an additional two patients, who have reached maximum cycles, are still in follow up for progression free survival

· The safety profile of AVA6000 continues to demonstrate a robust reduction in severe hematologic and cardiac toxicities that are associated with conventional dose doxorubicin

Based on this favorable efficacy and safety data observed in the Phase 1a trial, Avacta has initiated three Phase 1b expansion cohorts in triple negative breast cancer, soft tissue sarcoma and salivary gland cancer in the first and second line setting. Patients are screening and the first patients to be treated in these expansions are expected imminently in the US.

Avacta Announces Positive New Data from the AVA6000 Phase 1 trial Demonstrating Clinically Meaningful Tumor Shrinkage in Patients with Salivary Gland Cancers

Meaningful tumor shrinkage observed in five out of 10 patients with partial and minor responses and 90% disease control rate in patients with salivary gland cancers

Phase 1b expansion cohorts screening patients in triple negative breast cancer, soft tissue sarcoma and salivary gland cancer

NM

Let's say £68k isn't chicken feed. It's certainly a very confident and optimistic endorsement of SEE's prospects and that should ease concerns, if indeed any concerns exist.

I bet we see more director buying

I know the seller's still around but they'll disappear, eventually

205,000

1,170,000

S126

PANR is going to need cash to exploit their assets, fact. It's not a negative, it's a positive. Lots of upside here, over time though I think they'll be a subject to an offer.

By the way that's not a negative, a decent sized placing will underpin PANR's ability to exploit to the full their assets.. a placing is essential

Dilutive placing

You can buy at 3.95. God almighty, there must be an absolutely reservoir of stock available

commercial contracts badly needed to soak up the overhang

390k

Std

great write-up. ta

Slander and libel are civil offences and do not attract a custodial sentence.

PDMR / Director Dealing

Seeing Machines Limited (AIM: SEE, "Seeing Machines" or the "Company"), the advanced computer vision technology company that designs AI-powered operator monitoring systems to improve transport safety, announces that on 8 January 2025 Martin Ive, Chief Financial Officer, purchased a total of 150,000 ordinary shares ("Ordinary Shares") at a price of 4.20 pence per Ordinary Share. Further, on 9 January 2025, Martin Ive purchased a total of 135,000 Ordinary Shares at 4.13 pence per Ordinary Share and 4,746 Ordinary Shares at 4.19 pence per Ordinary Share.

Following these purchases, Mr Ive is now beneficially interested in 8,312,726 Ordinary Shares, representing 0.17 per cent. of the issued share capital of the Company.

The Notification of Dealing Form required in accordance with UK MAR is set out below.

Nm

On the cusp?

Https://www.linkedin.com/posts/seeingmachines_ces2025-aftermarket-auto-activity-7282932333358264320-k7V8

Bonzo - great post